OR WAIT null SECS
CordenPharma and Moderna extended a strategic manufacturing services agreement for the supply of lipid excipients to be used in Moderna’s vaccine against SARS-CoV-2.
CordenPharma, a contract development and manufacturing organization (CDMO) for APIs, drug products, and pharmaceutical packaging, extended their existing manufacturing agreement with Moderna to manufacture large-scale volumes of Moderna's lipid excipients to be used in the manufacture of Moderna's vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2), the companies announced in a May 28, 2020 press release.
The companies will further extend their supply relationship by expanding the manufacturing agreement originally signed in 2016 between Moderna and CordenPharma Switzerland. The amended agreement now includes CordenPharma Chenôve in France and CordenPharma Colorado in the US for larger-scale volumes of lipids. The expanded agreement will begin immediately to rapidly meet Moderna's increasing demand over the upcoming months, with an emphasis on securing long-term supply.